KPV
A potent anti-inflammatory tripeptide derived from the C-terminus of alpha-MSH that suppresses NF-kB signaling without melanocortin receptor activation.
Also known as: Lys-Pro-Val, Alpha-MSH C-terminal tripeptide, KPV tripeptide
Regulatory Status
Classification date: 2026-02-27
Reclassification to Category 1 announced but not yet formalized
Compounding: Not currently available for compounding
Evidence Summary
How It Works
KPV (Lys-Pro-Val) is the shortest active fragment of alpha-melanocyte-stimulating hormone, retaining its anti-inflammatory activity without melanotropic effects. It directly enters cells and translocates to the nucleus where it inhibits NF-kB activation, reducing production of pro-inflammatory cytokines (TNF-alpha, IL-6, IL-1beta). In gut tissue, it has demonstrated mucosal healing effects in colitis models by downregulating inflammatory pathways and promoting epithelial integrity.
Common Applications
Safety & Considerations
Minimal side effects reported in preclinical and limited clinical use. Does not produce tanning or melanotropic effects despite its alpha-MSH origin. Available in oral, topical, and injectable forms. Human clinical data is very limited. Currently not legal for compounding in the US.
Related Research
Regulatory classifications can change rapidly. The information shown here was last verified on 2026-02-27. Always confirm current legal status with a licensed provider or the FDA before making treatment decisions.